LAURUSLABS
OVERVALUEDLaurus Labs Limited
Pharma · NSE
↓ 180.3% vs fair value
52W Low
₹585
+129.3% from low
52W High
₹1,328
New 52W High 🚀
Valuation Gauge
Current Price
₹1,340
Fair Value
₹478
Fair Value Analysis
₹478
Based on earnings growth potential for Pharma sector companies | Sector-expensive: P/E at 86th percentile vs sector peers. | CAUTION: ROCE declining (latest 14.6%) — returns on capital are falling; verify this isn't a value trap.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Mixed Signals
Profitability
ROE of 17.7% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.5x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 79.9x is 1.9x the Pharma sector median of 42x — expensive
Cash Flow
Negative FCF of ₹-39 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of -24.4% — severe earnings decline
Dividend
Dividend yield of 0.2% is symbolic — low but positive
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-0.1%
Free cash flow / market cap
Revenue Growth (YoY)
+5.3%
Year-on-year revenue change
Profit Growth (YoY)
+21.0%
Year-on-year PAT change
Operating Cash Flow
₹602 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹16.5
P/E Ratio
79.9x
P/B Ratio
13.5x
ROE
17.7%
ROCE
11.9%
Debt / Equity
0.46x
Beta
—
Div Yield
0.2%
FCF (Cr)
₹-39 Cr
Revenue (Cr)
₹5,508 Cr
EPS Growth 5Y
-24.4%
Mkt Cap (Cr)
₹71,473 Cr
52W High
₹1,327.9
52W Low
₹584.5
Book Value/Share
₹97.2
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| 2026-03-31 | ₹6.8K Cr | ₹1.8K Cr | 26.0% | ₹890 Cr | ₹16.46 |
| 2025-03-31 | ₹5.6K Cr | ₹1.1K Cr | 19.0% | ₹358 Cr | ₹6.64 |
| 2024-03-31 | ₹5.0K Cr | ₹779 Cr | 15.0% | ₹162 Cr | ₹2.98 |
| 2023-03-31 | ₹6.0K Cr | ₹1.6K Cr | 26.0% | ₹793 Cr | ₹14.67 |
| 2022-03-31 | ₹4.9K Cr | ₹1.4K Cr | 29.0% | ₹832 Cr | ₹15.40 |
| 2021-03-31 | ₹4.8K Cr | ₹1.6K Cr | 32.0% | ₹984 Cr | ₹18.33 |
| 2020-03-31 | ₹2.8K Cr | ₹565 Cr | 20.0% | ₹255 Cr | ₹4.77 |
| 2019-03-31 | ₹2.3K Cr | ₹357 Cr | 16.0% | ₹94 Cr | ₹1.76 |
| 2018-03-31 | ₹2.1K Cr | ₹414 Cr | 20.0% | ₹168 Cr | ₹3.16 |
| 2017-03-31 | ₹1.9K Cr | ₹408 Cr | 21.0% | ₹190 Cr | ₹3.60 |
| 2016-03-31 | ₹1.8K Cr | ₹362 Cr | 20.0% | ₹134 Cr | ₹16.97 |
| 2015-03-31 | ₹1.3K Cr | ₹200 Cr | 15.0% | ₹68 Cr | ₹8.81 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86.4 | ₹469.7 | +81.6% | 7.7 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹118.2 | ₹237.8 | +50.3% | 26.8 | 5.2% | FAIRLY_VALUED |
Bal Pharma Limited | ₹82.3 | ₹147.5 | +44.2% | 15.7 | 12.6% | FAIRLY_VALUED |
Lincoln Pharmaceuticals Limited | ₹732.1 | ₹1,131.6 | +35.3% | 14.7 | 13.1% | FAIRLY_VALUED |
Zydus Lifesciences | ₹1,038.6 | ₹1,502.2 | +30.9% | 20.6 | 19.9% | UNDERVALUED |
Lupin | ₹2,270.7 | ₹3,112 | +27.0% | 19.5 | 26.9% | UNDERVALUED |
Natco Pharma | ₹1,170 | ₹1,571.3 | +25.5% | 13.8 | 18.0% | UNDERVALUED |
Sudeep Pharma Limited | ₹675 | ₹739.2 | +8.7% | 43.7 | 21.4% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant